Insights for Thought Leading Stakeholder Engagement to Decrease Medication Non-Adherence
Pharmaceutical companies have long recognized the importance of engaging key opinion leaders (KOLs) to gain insight and support for clinical research, drug development, and medical education.
With the rise of digital technology, pharma can now identify and engage a new generation of health care professionals (HCPs) who are leveraging social media to become influential digital opinion leaders.
In this post, we’ll look at four ideas that can help pharma unlock the power of these rising stars in health equity and clinical research. From understanding the impact of social media on prescribing habits to developing strategies for KOL engagement, we’ll explore how pharmaceutical companies can leverage these digital resources to drive meaningful change in patient care.
Consider Social Media’s Influence on Physician Behavior
First, it’s important to recognize the influence of social media on prescribing habits. A recent study found that physicians who use Twitter and other social media outlets are more likely to follow patient-centered approaches when it comes to choosing the best treatment for their patients.
According to the study, 41% of doctors think social media influences prescribing behavior. Among respondents, 9% said they “frequently” change the prescriptions they write based on information from social media, 32% said they do so “occasionally,” and 21% said they “never” do.
Connect to the Right Digital Opinion Leaders
Once pharma has identified digital opinion leaders (DOLs), they need to develop strategies for connecting with them. One way is through online forums dedicated specifically to medical influencers and patient advocacy groups. These forums provide users with an open platform to discuss medical research and share insights into how prescription drugs are being used in clinical settings.
By participating in these conversations, pharma can tap into a network of engaged HCPs who can provide valuable feedback on topics such as health literacy, medication adherence, and trustworthy scientific sources outside the ivory towers of academia.
Invest in Tech to Vet Potential KOLs
Pharmaceutical companies should also look at leveraging technology solutions that enable KOLs to be identified based on their expertise in a particular therapeutic area or specialty. For example, platforms like H1’s allow pharma professionals to find experienced professionals willing to engage in meaningful dialogue about relevant topics related to their field of expertise. This type of technology makes it easier for pharma companies to vet potential KOLs and ensure that they have the necessary knowledge and experience before reaching out for engagement opportunities.
Keep Health Equity at the Head of Your KOL Strategy
Pharmaceutical companies must prioritize health equity when engaging digital opinion leaders to further diversity of thought among HCPs that represent all patient populations. As more digital channels become available for sharing information about therapeutics and treatments, big pharma must take an active role in ensuring that everyone has equal access to these resources regardless of socioeconomic background or race/ethnicity. To do this successfully requires understanding the issues facing underserved populations and engaging key stakeholders from those communities as part of any KOL strategy.
Finding and leveraging digital opinion leaders is essential for pharmaceutical companies looking to stay at the forefront of new developments in medicine while maintaining trust among clinicians and patients alike. Developing strategies focused on engaging rising stars in health equity and clinical research will help ensure that new therapies are targeted toward those most in need while also elevating public discourse surrounding evidence-based medicine practices around the world.
For more information on how to leverage the H1 platform to find new and emerging DOLs, request a demo of H1’s lead KOL engagement and identification solution – HCP Universe.